1. Targeting the EGFR and immune pathways in squamous cell carcinoma of the head and neck (SCCHN): Forging a new alliance
- Author
-
Zhuo Gerogia Chen, Paolo Bossi, Jan B. Vermorken, Antti Mäkitie, Juan P. Rodrigo, Alfio Ferlito, Nabil F. Saba, Alessandra Rinaldo, Primoz Strojan, Missak Haigentz, and Robert P. Takes
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Drug Resistance ,Cetuximab ,Antineoplastic Agents ,Disease ,Article ,Antineoplastic Agents, Immunological ,Clinical Trials as Topic ,Combined Modality Therapy ,Drug Resistance, Neoplasm ,ErbB Receptors ,Head and Neck Neoplasms ,Humans ,Immunotherapy ,Signal Transduction ,Squamous Cell Carcinoma of Head and Neck ,Treatment Outcome ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Internal medicine ,Advanced disease ,medicine ,Basal cell ,Head and neck ,business.industry ,Egfr inhibition ,3. Good health ,Radiation therapy ,stomatognathic diseases ,030104 developmental biology ,Immunological ,030220 oncology & carcinogenesis ,Neoplasm ,Human medicine ,business ,Rare cancers Radboud Institute for Health Sciences [Radboudumc 9] - Abstract
Despite the recent approval of immune-modulatory agents, EGFR inhibition continues to be a cornerstone in the management of squamous cell carcinoma of the head and neck (SCCHN) namely in combination with radiotherapy in the treatment of locoregionally advanced disease as well as in platinum-sensitive recurrent or metastatic disease in the first-line setting. Importantly, recent evidence has emerged supporting also an immune-modulatory effect of EGFR inhibition, and interest has now focused on utilizing these effects in the current treatment approaches for SCCHN. In this report, we review the rationale and evidence supporting the forging of this new alliance in optimizing the treatment of SCCHN.
- Published
- 2019